Rameda Pharmaceuticals
Amr Morsy serves as the Chief Executive Officer and Board Member of Rameda Pharmaceuticals since January 2011, leading a team of over 2,000 employees to navigate significant challenges in the Egyptian market. Under Amr Morsy's leadership, Rameda emerged as the fastest-growing local pharmaceutical player from 2011 to 2018 and successfully listed on the Egyptian Stock Exchange in December 2019 with a market capitalization of USD 232 million. Prior to Rameda, Amr Morsy held the position of Chairman and Managing Director for Egypt and Sudan at Pfizer, contributing 17 years to various roles within the company. Academic credentials include a Graduate Diploma in Business Administration from Harvard Business School, an MBA from the Arab Academy for Science, Technology and Maritime Transport, and a Bachelor of Pharmacy from Alexandria University. Amr Morsy is committed to creating sustainable value aligned with the UN Sustainable Development Goals, particularly in diversity and inclusion, health, responsible consumption, and clean energy.
Rameda Pharmaceuticals
Our Vision: To become the most valuable emerging pharmaceutical company in Egypt. Our Mission: To provide our customers quality health care solutions in a cost effective manner by developing products and services that satisfy their health requirements. Establishment Rameda began operations in 1994 and was established by a group of Gulf investors with the intention of creating one of the largest pharmaceutical operations in the region. Owners hired V-Konsult of Germany to create a state-of-the art design. Contracted British Carter Construction company to build the Rameda’s facilities. Partnership with Alcon In 1999, Rameda entered into an agreement with Alcon to manufacture – under license - their ophthalmology products. In order to guarantee the quality of their products, Alcon built one of the highest quality eye production facilities in the region at Rameda. Quality enhancement Rameda renewed the syrup production to become GMP (Good Manufacturing Practice). A new Beginning In 2011, Compass Capital led a consortium of private equity investors for the acquisition of 100% of Rameda. Compass Capital plans to establish Rameda as a regional leader in the industry. To execute this strategy Rameda hired a new management team with a proven track record to complement the existing team. Company has commissioned M+W Group to transform solid dosage and beta lactam areas into GMP. Brining entire facility to compliance.